Table 1

Most frequent (≥4 or more patients in part A and/or >3 pts in part B) treatment-related adverse events

Part APart B
Efti (1 mg)/
pembro (n=6)
Efti (6 mg)/
pembro (n=6)
Efti (30 mg)/
pembro (n=6)
Total
(n=18)
Efti (30 mg)/
pembro (n=6)
Fatigue4 (66.7)1 (16.7)3 (50.0)8 (44.4)5 (83.3)
Injection site erythema1 (16.7)1 (5.6)4 (66.7)
Edema peripheral4 (66.7)
Diarrhea2 (33.3)3 (50.0)5 (27.8)1 (16.7)
Nausea1 (16.7)2 (33.3)2 (33.3)5 (27.8)2 (33.3)
Rash1 (16.7)2 (33.3)2 (33.3)5 (27.8)4 (66.7)
Arthralgia2 (33.3)1 (16.7)1 (16.7)4 (22.2)4 (66.7)
  • Results shown as: number of patients with adverse event (%).